ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

DonShimoda

rkrw

tktom

From: jaybe	9/30/2016 9:10:38 PM
	3 Recommendations of 4474

Spirit3 trial terminated, or more precisely cancelled... A few reasons cited, I'm sure Brexit didn't help either. The whole early switch question has already been answered positively for 2nd-gen TKIs, but lower cost of generic imatinib is challenging criteria used for establishing early failure. IMO the OPTIC-2L trial is more meaningful in establishing the better switch drug of choice, regardless of timing for switch. spirit3.spirit-cml.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next